Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/30/12 → 9/22/16 |
Funding
- The University of Chicago (5-27050 / HHSN261201100071C)
NCI UC12N01 / NCI 9165 / UC 12-1359: A randomized phase II trial of ARQ 197 (tivantinib)/cetuximab versus cetuximab in patients with recurrent/metastatic head and neck cancer: Subproject for Institution # SP0012448
- Kuzel, Timothy Michael (PD/PI)
- Agulnik, Mark (Co-Investigator)
Project: Research project